TubulisTubulis from Munich doses first Patient wi...Tubulis doses first patient in phase 1/2a trial investigating ADC candidate TUB-040 in ovarian cancer and lung adenocarcinoma (NSCLC). TUB-040 is a NaPi2b-targeting Exatecan ADC based on Tubulis’ proprietary … more ➔
Biosecure actBIOSECURE Act could affect half of US biop...The BIOSECURE Act of the United States could affect more than 120 US biopharmaceutical drugs partnered with Chinese companies ‘of concern’, as named in the bill. Of these, approximately half are in clinical … more ➔
Precision fermentationDanone, Michelin and DMC Biotechnologies o...French dairy giant Danone, engineering materials group Michelin, US start-up DMC Biotechnologies and Crédit Agricole Centre France have joined forces to create the Biotech Open Platform as precision … more ➔
Cancer ImmunotherapiesResearchers identify blockers of CNS effec...German researchers have tracked down the causes for central nervous system side effects of cancer immunotherapies and blocked them in small animal models. more ➔
CROEvotec SE cashes in €20m milestoneEvotec SE has reached a predefined milestone worth €20m in the CRO’s partnership with Bristol Myers Squibb (BMS). more ➔
FinancingTacalyx’ extends seed capital financ...Glycan target specialist Tacalyx GmbH expands its seed financing to €14m to advance its anti-TACA cancer therapies. more ➔
T CellsCRISPR screen highlights genes behind T ce...Researchers at University Hospital Hamburg-Eppendorf have laid the foundation to screen for molecules that shift Th17 cells from proinflammatory or immune-dampening mode. more ➔
acquisitionGSK closes US$50m acquisition with Elsie B... GSK takes over Elsie Biotechnologies in US$50m deal to boost its oligonucleotide-based drug platform and pipeline. more ➔
radiopharmaceuticalITM gets equity to launch Phase III lead r...ITM Isotope Technologies Munich SE has raised €188m ito boost radiopharma pipeline, contract manufacturing cpacity, and launch ITM-11. more ➔
CollaborationQuantro Therapeutics cashes in milestone p...Viennese biotech QUANTRO Therapeutics identifies small molecule targeting an onkogenic transcription factor in Boehringer Ingelheim collab. more ➔
